During the past decade, Amersham Buchler GmbH & Co. KG conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Amersham Buchler GmbH & Co. KG" are "Alzheimer's" (1 trials), "Aorto-iliac Stenosis" (1 trials), "Arterial Occlusive Diseases" (1 trials), "Lewy Body Dementia" (1 trials) and "Non-DLB Dementia" (1 trials). Many other conditions were trialed in "Amersham Buchler GmbH & Co. KG" in a lesser frequency.

Most popular intervention types in "Amersham Buchler GmbH & Co. KG" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Gadodiamide Injection" (2 trials) and "DatSCAN" (1 trials). Other intervention names were less common.

The vast majority of trials in "Amersham Buchler GmbH & Co. KG" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Amersham Buchler GmbH & Co. KG". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Amersham Buchler GmbH & Co. KG, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Amersham Buchler GmbH & Co. KG, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".